Abzena plots 6th biologics plant as demand for mammalian cell-line production continues to grow
With demand for biologics manufacturing at an all-time high, UK CDMO Abzena has rushed to add a bigger footprint to keep up. Now looking to expand its US presence, Abzena will tack on another manufacturing site — its third stateside.
Abzena said the expansion, which will be its sixth site, was driven by increased customer demand for commercial-scale manufacturing capacities across a wide array of therapeutic areas. The site’s exact location in the US wasn’t disclosed, but Abzena said it will increase its cGMP manufacturing capacity by adding four modular suites, each of which will house two 2,000-liter bioreactors in the first phase of construction.
A second phase will add another two suites with the 2,000-liter bioreactors, for a total of 12. The facility, Abzena said, will accommodate Phase III and commercial manufacturing, and will also be equipped to handle continuous manufacturing and perfusion by the middle of 2022.
Abzena didn’t share the cost of the project or the expected footprint.
Jonathan Goldman, Abzena’s CEO, said in a statement the new facility will build on the successes of the company’s second San Diego, CA facility, which launched near the end of last year. Abzena dumped $60 million into that 50,000-square-foot facility, which expanded the company’s offerings from early-stage to commercial biologic development capacities.
“We are pleased to provide integrated asset development with a full suite of in-house services from discovery through clinical and commercial phases without the need for technology transfer,” Goldman said of Tuesday’s newly-announced site.
Abzena began building its US presence in San Diego when it bought manufacturer PacificGMP in 2015 for $8.4 million.